Prevest Denpro Ltd

AGM notice and access details

• 27th AGM scheduled for Sept 17, 2026 via Video Conferencing.
• Cut-off date for voting eligibility is Sept 10, 2026.
• Electronic voting opens Sept 14, 2026 and ends Sept 16, 2026.
• Shareholders without registered emails received notice via link to AGM and AR.
• Notice and Integrated Annual Report accessible from company site and BSE/NSDL portals.

Financial performance

• Standalone revenue from operations ₹7,666.12 Lakhs, up 13.63% YoY.
• Standalone PAT ₹2,141.82 Lakhs, up 17.67% YoY.
• Consolidated revenue ₹7,672.36 Lakhs, up 13.93% YoY.
• Consolidated PAT ₹2,049.05 Lakhs, up 12.86% YoY.
• EBITDA up 16.65%; PBT up 17.58%; PAT up 17.67% YoY.
• UAE subsidiary established as part of international expansion.
• Final dividend of ₹1 per equity share proposed.
• Paid-up capital ₹12.003 crore; no new shares issued.
• Balance sheet remains debt-free.

Growth & strategic initiatives

• Overseas expansion: UAE subsidiary established; Axiodent Inc. in USA; Gulf General Trading LLC.
• Disinfectants business commercialized; new growth vertical.
• Digital dentistry portfolio expanded with next-gen 3D printing solutions.
• Rotoflex endodontic file system strengthened with strong market response.
• Global footprint expanded to 90+ countries; three overseas subsidiaries.
• MoU with IIT Kanpur for biomaterials; Prevest Research Institute recognized as DSIR center.
• EPIP plant capacity >200 MT/year; in-house raw-material synthesis.
• R&D: 20+ collaborations with dental colleges; focus on biomaterials and digital tech.
• Approximately 16 educational/clinical training programs conducted.

Governance & controls

• Board size six with two women; several KMP changes in 2025-26.
• Independent Directors declared independence; data bank maintained with IICA.
• Audit Committee reconstituted on 22-Apr-2026; NRC and other panels reconstituted.
• Statutory auditors appointed: A D V & Associates; prior: Mittal & Associates.
• Secretarial auditor: NKM & Associates; Internal auditor: VNB & Co; Cost auditor: PAN & Associates.
• Governance gaps noted: Reg 30 intimation lapses; ED remuneration excess; tenure intimation delays.
• Seven board meetings held in 2025-26; attendance details recorded.
• Independents comply with applicable codes; no director disqualification.

Dividends & capital management

• Final dividend of ₹1 per equity share; subject to shareholder approval.
• No transfer to general reserve during the year.
• Paid-up capital ₹12.003 crore; no new shares issued.
• SME listing on BSE; annual listing fees for 2025-26 paid.

CSR & sustainability

• CSR spend totaled ₹42.11 Lakhs; 2% average net profit obligation ₹44.43 Lakhs.
• Average net profit (last 3 years) ₹22.21 Crores.
• Projects cover education, healthcare, skill development, hunger relief, floods relief, plantation.
• Key initiatives include government school upgrades, Prevest Spark scholarships, apprenticeships.
• Administrative CSR overhead ₹0.72 Lakhs; openings balances tracked; website disclosures.
• CSR policy, projects and impact disclosures published on company website.
• Opening CSR balance negative; closing balance as of year end ₹-1.25 Lakhs.
• CSR expenditure aligned with Schedule VII; ongoing and non-ongoing projects disclosed.

Subsidiaries & consolidation

• Wholly owned subsidiaries: Denvisio Biomed Limited, Axiodent Inc., Prevest Denpro Gulf General Trading LLC.
• US and India subsidiaries fully owned; Dubai entity yet to commence operations.
• Consolidated results include all active subsidiaries; Dubai subsidiary shown with 0% holding.
• Annexure AOC-1 provides salient features of subsidiaries.

Outlook & risk

• Positive outlook driven by digital dentistry and disinfectants growth.
• Domestic expansion to Tier II/III markets; broader export footprint.
• Invest in digital workflows, 3D printing, and integrated restorative solutions.
• Continue localization and indigenous raw material initiatives to reduce import reliance.

AGM Details

• Date/time: 17 Sep 2026, 12:30 PM IST via VC/OAVM.
• Mode: VC/OAVM; deemed venue: registered office.
• Record date: 10 Sep 2026; remote e-voting: 14–16 Sep 2026.
• NSDL e-voting facility for remote voting.

Dividend

• Final dividend of ₹1 per equity share approved.

Ordinary Resolutions

• Adopt standalone and consolidated financial statements for FY 2025-26.
• Re-appoint Niharika Modi as Director by rotation.
• Appoint M/s ADV & Associates as Statutory Auditors for five years.

Special Resolutions

• Remuneration ratified for Pan & Associates Cost Auditor: ₹1 Lakh per year.
• Namrata Modi re-appointed Whole Time Director for 3 years.
• Remuneration up to ₹15 Lakh per month for Namrata Modi.
• Sai Kalyan Surapaneni re-appointed Executive Director for 3 years.
• Remuneration up to ₹70 Lakh per annum.
• Piyush Gupta appointed Independent Director for 5 years.
• Abhijeet Haridas appointed Independent Director for 5 years.
• Sukhen Pal Babuta appointed Independent Director for 5 years.
• Waiver of excess remuneration recovery for Sai Kalyan Surapaneni (2024-25, 2025-26).

Auditors

• Statutory auditors appointed for five-year term.
• Remuneration for 2026-27 proposed at ₹7.2 Lakh; subsequent years to be fixed by the Board.

Related Party Transactions

• Waiver of excess remuneration recovery constitutes related party transaction.

Director Changes

• Namrata Modi: Whole Time Director appointment for 3 years.
• Sai Kalyan Surapaneni: Executive Director appointment for 3 years.
• New Independent Directors: Gupta, Haridas, Babuta appointed for 5-year terms.

Standalone highlights

• Revenue from operations: ₹1,944.33 lakh, up 23.66% YoY; QoQ ₹1,890.40 lakh (+2.85%).

Standalone totals and profitability

• Total income: ₹2,077.40 lakh, up 22.96% YoY; QoQ ₹2,036.66 lakh (+2.00%).
• EBITDA: ₹821.88 lakh, up 22.60% YoY.
• PBT: ₹770.26 lakh, up 23.96% YoY.
• PAT: ₹578.23 lakh, up 24.77% YoY.

Consolidated highlights

• Revenue from operations: ₹1,906.83 lakh, up 20.94% YoY; QoQ ₹1,894.06 lakh (+0.67%).
• Total income: ₹2,038.36 lakh, up 20.38% YoY; QoQ ₹2,034.67 lakh (+0.18%).
• EBITDA: ₹808.14 lakh, up 24.73% YoY.
• PBT: ₹755.89 lakh, up 26.23% YoY.
• PAT: ₹563.86 lakh, up 27.99% YoY.

Dividend declaration

• Dividend declared: 10% (₹1 per equity share) for FY 2025-26, subject to shareholder approval.

Management commentary

• Management notes strong start to FY2026-27 with double-digit growth across key metrics.
• Consolidated results show revenue growth of 20.94% YoY and double-digit gains in EBITDA, PBT, PAT.
• Outlook remains optimistic with expansion plans domestically and internationally.

Record Date and Dividend Details

• Record date fixed as Saturday, September 05, 2026 for final dividend on equity shares.
• Dividend is subject to declaration at the 27th Annual General Meeting.

Consolidated results

• Revenue from operations: ₹1,906.83 lakh; Total Income: ₹2,038.36 lakh; Net profit: ₹563.86 lakh.
• EPS: basic ₹4.70; diluted ₹4.70.
• Total expenses: ₹1,282.47 lakh; PBT: ₹755.89 lakh; Tax: ₹192.03 lakh.
• YoY total income up about 20% to ₹2,038.36 lakh.
• Labour Codes increased employee benefit expense by ₹227.80 lakh.

Standalone results

• Revenue from operations: ₹1,944.33 lakh; Total Income: ₹2,077.40 lakh.
• Net profit: ₹578.23 lakh; EPS: basic ₹4.82; diluted ₹4.82.
• Total expenses: ₹1,307.14 lakh; PBT: ₹770.26 lakh; Tax: ₹192.03 lakh.
• YoY total income up about 23% to ₹2,077.40 lakh.

Dividend & AGM

• Final dividend proposed: 10% (₹1 per share) for FY2026, subject to AGM approval.
• AGM notice issued for 27th AGM.
• Dividend, if approved, paid within the prescribed timeline.

Review & disclosures

• Board approved unaudited results; limited review conducted.
• Foreign subsidiaries' results not material to the Group.
• Standalone results reviewed; no material misstatement.

Dematerialisation/rematerialisation status

• Regulation 74(5) not applicable; entire holding in demat form.
• No rematerialisation or dematerialisation requests were received during quarter ended 30 June 2026.

Financial Performance

• Revenue from operations rose 13.9% to INR 71.81 crores in FY26.
• Total income grew 14.4% to INR 76.72 crores.
• EBITDA rose 13.3% to INR 29.62 crores; EBITDA margin 38.6%.
• PBT rose 13.9% to INR 27.61 crores; PAT rose 12.9% to INR 20.49 crores.
• FY26 Q4: revenue from operations 18.94 crores; total income 20.35 crores; EBITDA 8.32 crores; PAT 5.82 crores.
• Q4 margins: EBITDA 40.87%, PBT 38.38%, PAT 28.61%.

Geography and Segments

• Domestic growth 9%; export growth 17.58% in FY26.
• Presence in 90–92 countries; diversified geographical footprint.
• UAE subsidiary established; operations delayed by Middle East tensions; opportunity remains strong.
• Dubai subsidiary opened in February; online sale planned next month; two staff.
• US market grew 37.58% YoY; Axiodent plus private labeling contributing.
• Rotoflex endodontic file system received encouraging response.

Capex and Production

• Installed capacity utilization around 67–68%; full-capacity turnover ~ INR 125 crores.
• New production line (digital dentistry, resins, disinfectants) currently 18–20% utilized.
• Indigenous 3D printer program targeted by 2028; Omni printers; 3D resins growth.
• 3D printer sales up 162% YoY; resins growth 40.5%.
• R&D progress: 2 products regulatory-ready; 4 licenses for new agents; TRL 7; raw-material substitution underway.

Outlook and Guidance

• Optimistic about opportunities; prudent given global uncertainty.
• Strengthen leadership in digital dentistry; invest in advanced digital solutions and R&D.
• Expand US presence via Axiodent; scale Oradox; grow disinfectants; deepen export markets.
• Domestic growth potential supported by rising healthcare expenditure and adoption of advanced dental tech.

Q&A Highlights

• Oradox sales declined 2% due to US export constraints.
• US market growth 38%; private labeling and online sales contributing.
• Dubai subsidiary progressing; online sale planned next month.
• 3D printing momentum: printers up 162%; resins up 40.5%.
• Indigenous 3D printer target by 2028; competition from MNCs; edge from cost.
• Domestic expansion into Tier 2/3; GST/weather disruptions impacted H1.

Risks and Watchpoints

• Geopolitical tensions and Middle East conflict disrupted export patterns.
• Shipping disruptions and global uncertainty affected performance in Q4.
• UAE commencement delays depend on geopolitical developments.